240 related articles for article (PubMed ID: 26722766)
21. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.
Conforti F; Pala L; Sala I; Oriecuia C; De Pas T; Specchia C; Graffeo R; Pagan E; Queirolo P; Pennacchioli E; Colleoni M; Viale G; Bagnardi V; Gelber RD
BMJ; 2021 Dec; 375():e066381. PubMed ID: 34933868
[TBL] [Abstract][Full Text] [Related]
22. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
Kim JE; Ahn JH; Jung KH; Kim SB; Kim HJ; Lee KS; Ro JS; Park YH; Ahn JS; Im YH; Im SA; Lee MH; Kim SY
Breast Cancer Res Treat; 2011 Jan; 125(1):99-106. PubMed ID: 20922564
[TBL] [Abstract][Full Text] [Related]
23. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
[TBL] [Abstract][Full Text] [Related]
24. Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis.
Abdel-Rahman O
Expert Rev Anticancer Ther; 2016 Aug; 16(8):885-91. PubMed ID: 27210216
[TBL] [Abstract][Full Text] [Related]
25. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials.
Mauri D; Valachis A; Polyzos NP; Tsali L; Mavroudis D; Georgoulias V; Casazza G
J Natl Compr Canc Netw; 2010 Mar; 8(3):279-86. PubMed ID: 20202461
[TBL] [Abstract][Full Text] [Related]
26. Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study.
Lelièvre L; Clézardin P; Magaud L; Roche L; Tubiana-Mathieu N; Tigaud JD; Topart D; Raban N; Mouret-Reynier MA; Mathevet P
Clin Breast Cancer; 2018 Dec; 18(6):e1311-e1321. PubMed ID: 30098917
[TBL] [Abstract][Full Text] [Related]
27. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.
Loibl S; Jackisch C; Lederer B; Untch M; Paepke S; Kümmel S; Schneeweiss A; Huober J; Hilfrich J; Hanusch C; Gerber B; Eidtmann H; Denkert C; Costa SD; Blohmer JU; Nekljudova V; Mehta K; von Minckwitz G
Breast Cancer Res Treat; 2015 Jul; 152(2):377-87. PubMed ID: 26109347
[TBL] [Abstract][Full Text] [Related]
28. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.
Houston S; Grieve RJ; Hickish T; Percival F; Hamilton E
J Med Econ; 2010 Mar; 13(1):162-7. PubMed ID: 20136578
[TBL] [Abstract][Full Text] [Related]
29. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
Cleeland CS; Body JJ; Stopeck A; von Moos R; Fallowfield L; Mathias SD; Patrick DL; Clemons M; Tonkin K; Masuda N; Lipton A; de Boer R; Salvagni S; Oliveira CT; Qian Y; Jiang Q; Dansey R; Braun A; Chung K
Cancer; 2013 Feb; 119(4):832-8. PubMed ID: 22951813
[TBL] [Abstract][Full Text] [Related]
30. Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication.
Calderone R; Nimako K; Leary A; Popat S; O'Brien ME
Eur J Cancer; 2011 Jul; 47(11):1603-5. PubMed ID: 21684152
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Andronis L; Goranitis I; Pirrie S; Pope A; Barton D; Collins S; Daunton A; McLaren D; O'Sullivan JM; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown JE; Chakraborti P; Hussain SA; Russell JM; Billingham LJ; James ND
BJU Int; 2017 Apr; 119(4):522-529. PubMed ID: 27256016
[TBL] [Abstract][Full Text] [Related]
32. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).
von Minckwitz G; Rezai M; Tesch H; Huober J; Gerber B; Zahm DM; Hilfrich J; Costa SD; Dubsky P; Blohmer JU; Denkert C; Hanusch C; Jackisch C; Kümmel S; Fasching PA; Schneeweiss A; Paepke S; Untch M; Burchardi N; Mehta K; Loibl S;
Eur J Cancer; 2016 Sep; 64():12-21. PubMed ID: 27323347
[TBL] [Abstract][Full Text] [Related]
33. AZURE subgroup analysis shows adjuvant therapy with zoledronic acid may benefit breast cancer patients postmenopausal >5 years.
Oncology (Williston Park); 2011 Nov; 25(12):1212-3. PubMed ID: 22229216
[No Abstract] [Full Text] [Related]
34. Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years.
Zhang C; Zhang F; Liang G; Zeng X; Yu W; Jiang Z; Ma J; Zhao M; Xiong M; Gui K; Yuan F; Ji W
BMC Musculoskelet Disord; 2018 Nov; 19(1):424. PubMed ID: 30497434
[TBL] [Abstract][Full Text] [Related]
35. Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
Brufsky AM
Expert Opin Pharmacother; 2008 Apr; 9(6):1013-28. PubMed ID: 18377343
[TBL] [Abstract][Full Text] [Related]
36. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
37. Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases.
Dincer M; Altundag K; Harputluoglu H; Aksoy S; Cengiz M; Gullu I
Med Oncol; 2008; 25(3):356-9. PubMed ID: 18196480
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer: Zoledronic acid--more than just a bone drug.
Mathew A; Brufsky A
Nat Rev Clin Oncol; 2014 Oct; 11(10):564-5. PubMed ID: 25200411
[TBL] [Abstract][Full Text] [Related]
39. Bone-modifying Agents (BMAs) in Breast Cancer.
Shapiro CL
Clin Breast Cancer; 2021 Oct; 21(5):e618-e630. PubMed ID: 34045175
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis.
He M; Fan W; Zhang X
J Hematol Oncol; 2013 Oct; 6(1):80. PubMed ID: 24283946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
